Lakefront Biotherapeutics NV (LKFT) stock
LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
$33.98+0.05 (+0.15%)
Close on Nov 13, 2026Market cap $2.24BP/E 6.3Yield –
Lakefront Biotherapeutics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was 4.87 EUR, up 334.8% from the year before. The highest annual figure on record is 4.87 EUR in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.87 EUR | +334.8% |
| FY2024 | Dec 31, 2024 | 1.12 EUR | -65.1% |
| FY2023 | Dec 31, 2023 | 3.21 EUR | – |
| FY2022 | Dec 31, 2022 | -3.32 EUR | – |
| FY2021 | Dec 31, 2021 | -1.58 EUR | – |
| FY2020 | Dec 31, 2020 | -4.69 EUR | -288.4% |
| FY2019 | Dec 31, 2019 | 2.49 EUR | – |
| FY2018 | Dec 31, 2018 | -0.56 EUR | – |
| FY2017 | Dec 31, 2017 | -2.34 EUR | -305.3% |
| FY2016 | Dec 31, 2016 | 1.14 EUR | – |
| FY2015 | Dec 31, 2015 | -3.32 EUR | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2021 | Jun 30, 2021 | -0.98 EUR | – |
| Q2 FY2020 | Jun 30, 2020 | -1.77 EUR | – |
| Q2 FY2019 | Jun 30, 2019 | -0.86 EUR | – |
| Q2 FY2018 | Jun 30, 2018 | -0.42 EUR | – |
| Q2 FY2017 | Jun 30, 2017 | -0.71 EUR | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?